MedTrace Logo

Anticoagulation in Gastroesophageal Varices and JAK2 Mutation

NCT04527666 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2020-08-27

No results posted yet for this study

Summary

Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life, morbidity, and mortality of MPN patients mainly depend on disease-related symptoms, thromboembolic and hemorrhagic complications. Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. The aim of this study is to evaluate the efficacy of anticoagulation in patients with JAK2 mutation and gastroesophageal varices.

Conditions

  • Gastroesophageal Varices
  • JAK2 Mutation
  • Myeloproliferative Neoplasm

Interventions

DRUG

Anticoagulation Agents

Patients receive anticoagulation agents including low molecular weight heparin, warfarin, rivaroxaban, et al.

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2021-09-30
Completion
2022-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04527666 on ClinicalTrials.gov